Bronchitol sales just started not long ago.
Current approved market size (AU & EU for Adult) is only around $75m p.a, and only Germany & UK are on sale.
The market share for US and EU for children is around 4 times of current approved market share, being $290m.
In addition, the bronchiectasis could target a $800m market share, although trial III results were disappointed.
PXS is still a junior/developer, it can't be valued used PE ratio. Compared with other Bio juniors, QRX, PBT, PRR, TIS, all of them don't have any sales, but their individual E/V is much higher than PXS', basically PXS has no enterprise value at current market cap.
- Forums
- ASX - By Stock
- ann. out- investor presentation
Bronchitol sales just started not long ago. Current approved...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.4¢ |
Change
0.002(9.09%) |
Mkt cap ! $28.65M |
Open | High | Low | Value | Volume |
2.2¢ | 2.5¢ | 2.2¢ | $12.04K | 509.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 82668 | 2.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.4¢ | 100000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 82668 | 0.023 |
2 | 338839 | 0.022 |
5 | 1736248 | 0.021 |
11 | 2801008 | 0.020 |
2 | 999988 | 0.019 |
Price($) | Vol. | No. |
---|---|---|
0.024 | 100000 | 1 |
0.025 | 100000 | 1 |
0.026 | 50000 | 1 |
0.027 | 200000 | 1 |
0.028 | 500000 | 1 |
Last trade - 15.57pm 28/06/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online